Loading…
United StatesSaved
The New York Academy of Sciences brings researchers together for two hybrid days of talks on vaccines and immune therapies, from neurodegenerative disease and cancer to viral and bacterial diseases.
All times are local to the venue · America/New York
The programme moves between different questions about immune-based approaches to chronic disease: Alzheimer’s research and individualized cancer vaccines on Tuesday, then HPV, Lyme disease, tuberculosis and other infectious-disease topics on Wednesday. The mix makes this a research symposium spanning several fields, rather than a meeting devoted to one disease or treatment.
The New York Academy of Sciences frames the symposium around research into using vaccines and immunotherapies to prevent, delay or treat chronic disease. Its wider scope includes Alzheimer’s disease, Parkinson’s disease, cancer, multiple sclerosis, chronic hepatitis B, HIV and HPV-associated disease. The event description also names autoimmune disorders and identifies obesity and addiction as possible future areas; those are broader themes, not sessions on the posted agenda.
That distinction helps set expectations: the scheduled talks concentrate on neurodegenerative disease, cancer, viral and bacterial disease, and industry research updates. The meeting is presented by the Academy’s Microbiology and Infectious Diseases Discussion Group, whose broader work addresses biomedical research and public-health challenges related to infectious diseases.
Further reading: Vaccines and Immune Therapies for Chronic Diseases - NYAS ↗ · Sponsors: Vaccines and Immune Therapies for Chronic Diseases ↗ · Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
After welcome remarks from Megan Prescott, PhD, the opening keynote is by Rino Rappuoli, MD, PhD, of the Biotecnopolo di Siena Foundation. The neurodegenerative-disease session then puts Howard Feldman’s work on Alzheimer’s immunotherapy and vaccines beside Pascal Geldsetzer’s research topic on shingles vaccination rollouts and dementia prevention. The question mark in Geldsetzer’s listed talk title matters: the agenda identifies a subject of investigation, not a finding or a medical recommendation. A third talk in this session has not yet been announced.
The afternoon turns to cancer. After short talks selected from submitted abstracts and a networking lunch with a poster session, the cancer block includes an unannounced slot, Clemens Krepler of Merck on individualized mRNA neoantigen therapy for melanoma, and Vinod Balachandran of Memorial Sloan Kettering Cancer Center on personalized pancreatic-cancer vaccines. A later panel focuses on real-world evidence, innovation and clinical-trial design, adding questions about how research is evaluated to the disease-specific talks.
Further reading: Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
The second day opens with David Weiner of the University of Pennsylvania on therapeutic HPV vaccines. Two further talks in the viral-disease session remain unannounced. After a networking break, the bacterial-disease session includes a Lyme disease vaccine talk by James Groark of Pfizer, Paul Cockle of Denteric on therapies for Porphyromonas gingivalis-related diseases, and Alexander Schmidt of the Gates Foundation on the M72 tuberculosis vaccine.
Following the networking lunch, the industry-updates session has one unannounced slot and two scheduled AstraZeneca talks. Philip Swanson’s topic is AZD6750 and hepatitis B virus-specific CD8+ T-cell activation; Stacey Cromer Berman’s is development of a bispecific antibody for bronchiectasis patients chronically colonized with Pseudomonas aeruginosa. The programme then lists a closing keynote by Peter Marks of Eli Lilly and Company, followed by closing remarks from Megan Prescott.
Further reading: Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗ · Speakers: Vaccines and Immune Therapies for Chronic Diseases ↗
Researchers at all levels and across disciplines and sectors may submit work for consideration for a short talk or poster session. The deadline is January 15, 2027. The agenda already includes abstract-selected short talks and a poster session, so submitting is a separate option for people interested in presenting, not a requirement for attending.
Further reading: Vaccines and Immune Therapies for Chronic Diseases ↗ · Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
The agenda moves from neurodegenerative disease and cancer on Tuesday to viral and bacterial disease and industry updates on Wednesday. It also includes abstract-selected short talks, a poster session, networking breaks and a panel on real-world evidence and clinical-trial design. Several talk slots remain unannounced; the posted agenda gives the individual session times.
Tuesday, March 16, 2027: check-in begins at 8:30 a.m. ET, and the agenda runs through 5:15 p.m. Wednesday, March 17: check-in begins at 8:30 a.m. ET, and the final listed session runs from 4:10 to 5 p.m. The event overview gives an overall range ending at 5:15 p.m. Wednesday, but the posted agenda’s final session ends at 5 p.m.
Vaccines and Immune Therapies for Chronic Diseases - NYAS ↗ · Vaccines and Immune Therapies for Chronic Diseases ↗ · Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
The event is listed as hybrid, with separate in-person and virtual registration rates. The listing does not specify which poster, break or networking activities are available to virtual attendees. The planner contact listed for the event is [email protected].
Vaccines and Immune Therapies for Chronic Diseases - NYAS ↗ · Vaccines and Immune Therapies for Chronic Diseases ↗
The event listing gives the location as 115 Broadway, 8th Floor, New York, NY 10006.
In-person and virtual rates, respectively, are: member, $455 and $160; member student, postdoc and fellow, $180 and $65; nonmember student, postdoc and fellow, $230 and $80; nonmember academia and nonprofit, $570 and $200; and nonmember general entry and corporate, $680 and $240.
Vaccines and Immune Therapies for Chronic Diseases ↗ · Vaccines and Immune Therapies for Chronic Diseases ↗
Researchers at all levels and across disciplines and sectors may submit work for consideration for a short talk or poster session. The event materials state the deadline but do not provide a separate submission link.
Vaccines and Immune Therapies for Chronic Diseases ↗ · Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
The confirmed event destination is 115 Broadway, 8th Floor, New York, NY 10006. The event listing does not provide transit, parking or access-facility instructions. Use the map links to calculate directions from your own starting point.
Yes. The symposium is listed as hybrid and has virtual registration rates that vary by attendee category. The listing does not specify which poster, break or networking activities are offered online.
Vaccines and Immune Therapies for Chronic Diseases - NYAS ↗ · Vaccines and Immune Therapies for Chronic Diseases ↗
The posted agenda’s final session runs from 4:10 to 5 p.m., with closing remarks listed at 4:55 p.m. The event overview gives an overall date range through 5:15 p.m. Wednesday.
Vaccines and Immune Therapies for Chronic Diseases - NYAS ↗ · Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
Researchers at all levels and across disciplines and sectors may submit work for consideration. The deadline is January 15, 2027.
Vaccines and Immune Therapies for Chronic Diseases ↗ · Agenda: Vaccines and Immune Therapies for Chronic Diseases ↗
115 Broadway, 8th Floor, New York, NY 10006
Map search by venue and address. Check the organiser’s entrance details before travelling.
Images from the linked sources. Each caption identifies the context of the image.
Event, planning and background information checked 2026-11-03 against the linked sources.